TB-500 Fragments, BPC-157, Regen Peptide Stacks, N-Acetyl Epitalon, and GHRP-2 vs GHRP-6: A Clinical Reference Guide

What TB-500 Fragments Are and How They Work

TB-500 is a shortened, synthetically produced version of thymosin beta-4 (Tβ4), a ubiquitous intracellular protein encoded by the TMSB4X gene. The biologically active core sequence runs from residues 17 to 23: Ac-LKKTETQ. This seven-amino-acid fragment retains the actin-binding property of the full protein while offering improved solubility and a smaller molecular footprint for subcutaneous delivery.

Thymosin beta-4 promotes G-actin sequestration, which keeps monomeric actin available for cytoskeletal remodeling during wound closure and angiogenesis. A 2010 paper published in the Annals of the New York Academy of Sciences by Goldstein and Kleinman documented Tβ4's capacity to stimulate keratinocyte and endothelial cell migration at nanomolar concentrations, a finding relevant to tendon and skin repair models [1]. A separate study in rats demonstrated that systemic Tβ4 administration reduced infarct size after myocardial injury and improved fractional shortening by roughly 10% [2].

Clinically, the fragment format matters. Full-length Tβ4 contains 43 residues and degrades rapidly in plasma. The Ac-LKKTETQ fragment resists peptidase cleavage longer, making subcutaneous dosing at 2.0 to 2.5 mg twice weekly a practical approach for musculoskeletal indications. That dosing interval is drawn from compounding pharmacy protocols reviewed by sports medicine physicians, not from a phase-II trial, so individual variation should be expected [3].

Anti-inflammatory activity is a secondary but clinically meaningful property. Tβ4 and its fragments down-regulate NF-kB signaling, which lowers prostaglandin E2 and IL-6 production at injury sites. One rodent tendon-repair model showed a 40% reduction in inflammatory cytokines compared with saline controls after 14 days of treatment [4].

BPC-157 Fragments: Mechanisms and Clinical Relevance

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a portion of human gastric juice protein BPC. Its sequence, GEPPPGKPADDAGLV, does not correspond to any single endogenous protein fragment but was isolated from gastric secretions studied for mucosal protection. Sikiric and colleagues at the University of Zagreb have published extensively on its properties in rodent models since the 1990s [5].

The peptide's primary actions include:

• Upregulation of vascular endothelial growth factor (VEGF) and VEGFR2 signaling, accelerating neovascularization at injury sites [6]
• Dose-dependent protection of gastric mucosa against NSAID-induced lesions in rat models, with full mucosal protection at 10 mcg/kg [7]
• Modulation of the dopaminergic and serotonergic systems, which may explain reported effects on mood and gut motility [8]

Oral BPC-157 appears to exert local gastrointestinal effects without requiring systemic absorption, while subcutaneous injection produces measurable systemic concentrations detectable in muscle and tendon tissue within 30 minutes in rodent pharmacokinetic studies [5]. Human pharmacokinetic data remain unpublished as of this writing.

A 2021 review in Biomedicines concluded that BPC-157 "demonstrates consistent healing effects across multiple organ systems in preclinical models," though the authors explicitly noted the absence of phase-I human safety data as a gap that prevents clinical recommendation [9]. The standard compounding dose sits at 250 to 500 mcg daily, though some protocols use split dosing of 250 mcg morning and 250 mcg evening for systemic indications.

Gut permeability is an area of growing interest. BPC-157 reduced intestinal permeability markers in a rat inflammatory bowel model by 55% relative to controls, partly through tight-junction protein upregulation (ZO-1 and occludin expression) [10]. This mechanism makes it a candidate adjunct for patients on chronic NSAIDs undergoing tissue repair, though human data confirming this effect are needed.

Regen Peptide Stacks: Rationale and Composition

A regen peptide stack combines two or more peptides with non-overlapping mechanisms to address multiple steps of the repair cascade simultaneously. TB-500 acts on actin dynamics and angiogenesis. BPC-157 acts on VEGF signaling and mucosal repair. Growth hormone secretagogues like GHRP-2 raise insulin-like growth factor-1 (IGF-1), which drives collagen synthesis and satellite cell activation in muscle.

The table below maps each peptide to its primary repair target, helping clinicians select components based on the injury type:

| Peptide | Primary Target | Typical Dose | Route | |---|---|---|---| | TB-500 | Actin remodeling, angiogenesis | 2.0-2.5 mg 2x/week | Subcutaneous | | BPC-157 | VEGF signaling, mucosal repair | 250-500 mcg/day | Subcutaneous or oral | | GHRP-2 | GH/IGF-1 axis, collagen synthesis | 100-200 mcg 2-3x/day | Subcutaneous | | GHRP-6 | GH release, appetite stimulation | 100-200 mcg 2-3x/day | Subcutaneous | | N-Acetyl Epitalon | Telomerase, circadian regulation | 10 mg/night x 10-20 days | Subcutaneous |

Stacking is not a regulatory concept, and no published trial has evaluated a multi-peptide regen protocol as a single intervention. Physicians prescribing these combinations rely on additive pharmacology reasoning, not combination trial data. A conservative approach uses TB-500 and BPC-157 together during an acute injury phase, then adds a growth hormone secretagogue during the recovery phase when anabolic signaling becomes the rate-limiting factor.

Timing matters as well. GHRP-2 or GHRP-6 should be injected in a fasted state or at least 90 minutes after the last meal to avoid blunting the GH pulse with elevated somatostatin driven by food-stimulated insulin [11]. TB-500 and BPC-157 timing relative to meals is not established in the literature.

N-Acetyl Epitalon: Telomerase Activation and Circadian Biology

Epitalon (also spelled epithalone) is a tetrapeptide with the sequence Ala-Glu-Asp-Gly, first isolated from bovine pineal gland extract by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. N-acetyl epitalon adds an acetyl group at the N-terminus, which modestly improves membrane permeability and may extend half-life.

Khavinson et al. published data in 2003 showing that epitalon activated telomerase in human fetal fibroblasts and increased telomere length by roughly 33% in vitro over a 45-day exposure period [12]. This finding attracted wide attention, though it was a cell culture experiment, not a controlled human trial. A separate study in elderly patients (N=14) reported normalization of melatonin and cortisol secretion after a 10-day intravenous epitalon course, suggesting interaction with the hypothalamic-pituitary axis [13].

The anti-aging framing of epitalon centers on two properties: telomerase induction and pineal restoration. Melatonin production declines roughly 10 to 15% per decade after age 40, and blunted melatonin correlates with poor sleep architecture, impaired immune surveillance, and elevated oxidative stress markers [14]. Epitalon's reported ability to restore pineal output could be mechanistically relevant, though the human evidence is limited to small, older studies from a single research group.

N-acetyl epitalon at 10 mg subcutaneous each evening for 10 to 20 consecutive days is the most commonly cited compounding protocol. Some longevity clinicians use quarterly cycles. The safety profile in published rodent studies is benign, with no hepatotoxicity or mutagenicity signals at doses far exceeding the human equivalent, but post-market pharmacovigilance data in humans are essentially nonexistent [15].

GHRP-2 vs GHRP-6: Choosing the Right Growth Hormone Secretagogue

GHRP-2 (pralmorelin) and GHRP-6 are both synthetic hexapeptides that bind the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, stimulating pulsatile GH release. They differ enough in their receptor pharmacology that the choice between them changes clinical outcomes meaningfully.

GHRP-2 is the more selective compound. It produces a stronger, cleaner GH pulse with minimal effect on ghrelin-mediated appetite pathways at standard doses of 100 to 200 mcg. A crossover study (N=21) published in the Journal of Clinical Endocrinology and Metabolism showed that GHRP-2 at 1 mcg/kg IV elevated mean GH from 1.2 to 52.4 ng/mL, a 43-fold increase, with a return to baseline by 90 minutes [16]. Cortisol and prolactin rose modestly but remained within reference ranges.

GHRP-6 produces a comparable GH pulse but also drives a pronounced appetite increase within 20 to 30 minutes of injection. This occurs because GHRP-6 activates peripheral ghrelin signaling more strongly than GHRP-2 does. In a double-blind placebo-controlled trial (N=32), GHRP-6 at 100 mcg subcutaneous increased caloric intake at a subsequent ad libitum meal by an average of 36% compared with saline [17]. That appetite effect is a bug for patients managing body composition and a feature for those with cancer cachexia or post-surgical anorexia.

IGF-1 response is the downstream metric that matters for tissue repair. Both peptides raise serum IGF-1 when used three times daily, typically by 30 to 60 ng/mL above baseline over a 4-week period, which sits within the upper quartile of normal for most adults [18]. Combining either GHRP with a GHRH analog such as CJC-1295 or modified GRF(1-29) amplifies the GH pulse area under the curve roughly 3- to 4-fold compared with either peptide alone [19].

For a regen stack targeting musculoskeletal recovery in a patient without appetite concerns, GHRP-2 at 100 to 200 mcg injected before bed (in the fasted state) is the preferred choice. For oncology-adjacent or post-surgical wasting contexts, GHRP-6 at the same dose may be more appropriate given its appetite-stimulating profile.

Cortisol monitoring matters. GHRP-2 raises cortisol about 20 to 40% above baseline in the first 30 minutes post-injection. Patients with elevated baseline cortisol or active adrenal insufficiency should have morning cortisol checked before initiating any GHRP protocol [20].

Safety Considerations, Regulatory Status, and Compounding Risk

No peptide covered in this article holds current FDA approval for clinical use in humans outside of an IND (Investigational New Drug) framework. GHRP-2 (as pralmorelin) has been approved in Japan as a GH-deficiency diagnostic agent, but that indication does not transfer to off-label therapeutic use in the United States [21]. BPC-157, TB-500, and epitalon have no FDA-approved indication.

The FDA issued guidance in 2023 identifying certain peptides, including BPC-157, as having "safety concerns that preclude inclusion in a compounded drug product" outside of an approved pathway [22]. Compounded products are not subject to the same batch sterility, potency, and purity testing that FDA-approved drugs undergo, which means patients receiving compounded peptide injections carry a real, if poorly quantified, risk of contamination or mislabeled concentration.

Oncologic safety is the most frequently cited concern with growth-promoting peptides. IGF-1 at supraphysiologic levels is a mitogenic signal. A meta-analysis of 17 prospective cohort studies found that circulating IGF-1 in the top quartile was associated with a relative risk of 1.49 for colorectal cancer compared with the bottom quartile (95% CI 1.14 to 1.95) [23]. This does not mean therapeutic GH secretagogue use causes cancer, but it argues for monitoring IGF-1 and avoiding use in patients with active malignancy or strong family histories of hormone-sensitive cancers.

Practical safety monitoring for a regen stack should include:

• Fasting serum IGF-1 at baseline and at 6 weeks of GHRP use [18]
• Morning cortisol at baseline before GHRP initiation [20]
• Liver function panel at baseline for BPC-157 protocols longer than 8 weeks
• Blood pressure at each visit, as TB-500 may lower blood pressure through nitric oxide pathways in some patients [4]

Patients with a body mass index <18.5 kg/m² or active eating disorders should not receive GHRP-6 without close dietary supervision, given the 36% appetite amplification noted above [17].

Dosing Timelines and Cycle Structures

Acute injury protocols typically run 4 to 6 weeks, with TB-500 at 2.0 to 2.5 mg twice weekly and BPC-157 at 250 to 500 mcg daily. After the loading phase, some clinicians reduce TB-500 to a weekly maintenance dose of 2 mg for an additional 4 weeks while keeping BPC-157 daily.

GHRP-2 or GHRP-6 cycles generally run 8 to 12 weeks at 100 to 200 mcg per injection, administered 2 to 3 times daily (upon waking, pre-workout, and before sleep). Longer cycles are used but require IGF-1 monitoring to avoid sustained supraphysiologic levels [18].

N-acetyl epitalon is typically used in discrete cycles: 10 mg nightly for 10 to 20 consecutive days, repeated 2 to 4 times per year. Some longevity-oriented protocols extend to 20 days twice yearly. No comparative trial has determined the optimal cycle length [15].

A combined regen protocol might look like:

• Weeks 1 to 6: TB-500 2.0 mg subcutaneous Monday and Thursday + BPC-157 500 mcg subcutaneous daily
• Weeks 1 to 12: GHRP-2 100 mcg subcutaneous before bed on an empty stomach
• Weeks 7 to 16: TB-500 2.0 mg subcutaneous weekly (maintenance) + BPC-157 250 mcg daily
• Annually: N-acetyl epitalon 10 mg nightly for 14 nights, two cycles per year

These timelines are based on compounding pharmacy clinical protocols and expert opinion, not phase-III trial data. A prescribing physician should adjust based on the patient's IGF-1 response, injury severity, and tolerance.

Peptide storage affects potency. Lyophilized TB-500 and BPC-157 should be reconstituted with bacteriostatic water and stored at 2 to 8 degrees Celsius. Reconstituted solutions generally remain stable for 28 to 30 days refrigerated, though formal stability data for compounded preparations vary by pharmacy [3].